Mark Patrick Healy
GlaxoSmithKline
32 Papers
289 Citations
Mark Patrick Healy is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Cycloisomerization & Enyne. The author has an hindex of 12, co-authored 32 publications. Previous affiliations of Mark Patrick Healy include Novartis.
Chat about Author
Papers
Hydrogen‐Borrowing and Interrupted‐Hydrogen‐Borrowing Reactions of Ketones and Methanol Catalyzed by Iridium
Di Shen,Darren L. Poole,Camilla C. Shotton,Anne F. Kornahrens,Mark Patrick Healy,Timothy J. Donohoe +5 more
TL;DR: A one-pot methylenation/conjugate addition protocol to be developed, which greatly expands the range of products that can be made by this methodology.
Discovery of novel, non-acidic 1,5-biaryl pyrrole EP1 receptor antagonists.
Adrian Hall,Stephen John Atkinson,Susan H. Brown,Iain P. Chessell,Anita Chowdhury,Gerard Martin Paul Giblin,Paul Goldsmith,Mark Patrick Healy,Karamjit S. Jandu,Matthew R. Johnson,Anton D. Michel,Alan Naylor,Jennifer Sweeting +12 more
TL;DR: Replacement of the carboxylic acid group in a series of previously described 1,5-biaryl pyrrole EP1 receptor antagonists led to the discovery of various novel non-acidic antagonists that displayed high binding affinity and high binding efficiency indices.
39
Patent
Pyrazole compounds as prostaglandin receptors ligands
Elizabeth Ann GlaxoSmithKline Conway,Gerard Martin Paul GlaxoSmithKline Giblin,Mairi Gibson,Adrian Hall,Thomas George Christopher Hayhow,Mark Patrick Healy,David Nigel Hurst,Ian Reginald Kilford,Stephen Carl Mckeown,Alan Naylor,Helen Susanne Price,Derek Anthony Rawlings +11 more
- 24 Apr 2006
TL;DR: In this paper, the authors define a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of these compounds in medicine, where Z, R1, R2a, R2b, R10, R11 and Rx are as defined in the specification.
37
Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.
Adrian Hall,Stephen John Atkinson,Susan H. Brown,Iain P. Chessell,Anita Chowdhury,Nicholas Maughan Clayton,Tanya Coleman,Gerard Martin Paul Giblin,Robert Gleave,Beverley Hammond,Mark Patrick Healy,Matthew R. Johnson,Anton D. Michel,Alan Naylor,Riccardo Novelli,David J. Spalding,Sac P. Tang +16 more
TL;DR: The preliminary SAR of a series of novel 1,5-biaryl pyrrole EP1 receptor antagonists derived from compound 1 is described and the most effective replacement was found to be the isobutyl group.
31
Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist.
Mairi Sime,Amanda C. Allan,Paul B. Chapman,Charlotte Fieldhouse,Gerard Martin Paul Giblin,Mark Patrick Healy,Millard H. Lambert,Lisa M. Leesnitzer,Ann Lewis,Raymond V. Merrihew,Richard A. Rutter,Rosemary Sasse,Barry G. Shearer,Timothy M. Wilson,Robert X. Xu,David Virley +15 more
TL;DR: The optimization ofPPARγ activity and in vivo pharmacokinetics leading to the identification of GSK1997132B a potent, metabolically stable and centrally penetrant PPARγ partial agonist, is described.
31